Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 329550
(i) use, Develop, have Developed, Commercialize and conduct Medical Affairs for the Products in the Field in the Licensee Territory, and
(ii) Package and have Packaged the Products for use in the Field in the Otsuka Territory.
This agreement includes an exclusive and non-exclusive grant back from Licensee to Licensor.
Voclosporin is a novel, investigational, orally administered treatment developed to treat patients with LN, a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus (SLE).
Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys.
IPSCIO Record ID: 234465
Dry Eye Syndrome (DES)
Focal segmental glomerulosclerosis (FSGS)
Lupus nephritis (LN)
Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye
Focal segmental glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.
Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE).
IPSCIO Record ID: 304790
IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.
Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.
IPSCIO Record ID: 367351
Licensor grants a non-exclusive license, with the right to sublicense, under the Other Licensed Patents, solely to research, develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Field in the Territory; provided, however, that no license is granted under the Other Licensed Patents to any clinically active ingredient other than Licensed Molecule.
Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How, solely to research, develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Field in the Territory; provided, however, that no license is granted under the Licensed Know-How to any clinically active ingredient other than Licensed Molecule.
BAFF Peptibody shall mean a fusion protein comprising a peptide generated by methods described in the AMG 623 Licensed Products that bind to BAFF as the primary intended therapeutic mechanism of action and a constant domain of an antibody or any other moiety intended to extend the half-life of such peptide. For purposes of this definition, AMG 523 shall be deemed a BAFF Peptibody.
BAFF shall mean B-Cell Activating Factor. BAFF is also referred to as TALL-1 and AGP-3 in the patents and patent applications within the Licensed Patents.
AMG 623 is a peptide fusion protein, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases
Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels.
IPSCIO Record ID: 28853
â€œLicenceâ€ shall mean an exclusive, worldwide, sublicenseable licence to use the Licensed Information and under the Patents, for the research, development, production, marketing and sale of Products, subject to the provisions of clause 4 below and the other terms and conditions of this Agreement.
U.S.A* 08/913,994 – 6,613,536
A method to dissolve the peptide (hCDR1) in PBS for the tolerogenic administration.
Mode of injection of hCDR1 for the prevention of an autoimmune response.
Characterization of the isotypes of the antibodies produced following a chronic treatment with hCDR1.
Binding of hCDR1 to MHC class II on APC in comparison with control peptides.
Determination of complement C3 levels in sera of mouse models and effects of treatment with hCDR1.
Assays for the evaluation of the effects of treatment with hCDR1 in the presence of immunosuppressive drugs (such as Methotrexate, Mofetil Mycophenolate, Immuran) used for the treatment of lupus (especially lupus nephritis).
Methods to assess the effects of treatment with hCDR1 on CNS lupus (pathology and behavior dysfunction) in spontaneous and induced experimental SLE.
Determination of anti-NMDA specific antibodies in sera of mice with induced lupus and the effects of hCDR1 on the latter.
Induction of neurogenesis and expression of BDNF in brains of SLE afflicted mice following treatment with hCDR1.
Methods to determine B cell dysfunction and the effect of hCDR1 on the latter especially in the target organs of lupus, namely, brain and kidney.
Evaluation of hCDR1 activity using a short term in vitro assay. This method was used in one of our publications and is written in the Methods section. However, because this technology can be used in the future to determine whether a patient might be a responder to the treatment of hCDR1 (which is not mentioned in the publication) we think that it might be the most important know how of the whole list.
IPSCIO Record ID: 166419
Systemic lupus erythematosus also known simply as lupus, is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body.
'Licensed Patent(s)' means any Letters Patent issued upon STANFORD's U.S. Patent Application, Serial Number 07/958,911 filed October 9, 1992, and/or any divisions, continuations, continuations-in-part or reissues thereof, and/or any foreign patents corresponding thereto.
IPSCIO Record ID: 337709
ITP means immune thrombocytopenia where the immune system attacks and destroys the bodyâ€™s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.
AIHA means autoimmune hemolytic anemia. It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.